Table 3. Clinical information of trials using CAG regimen in this study.
| Study | Patients (NO.) | Type of Disease | Median age (range) | Cytarabine dosage | Aclacinomycin dosage | CR (%) |
|---|---|---|---|---|---|---|
| Li[78] | 12 | MDS | 53 (40–76) | 10mg/m2/12h×14d | 14mg/m2/d×4d | 50 |
| Su[68] | 52 | AML (Elderly) | NR | 10mg/m2/12h×14d | 10-14mg/m2/d×4d | 73.08 |
| Li[65] | 22 | AML (Elderly) | 68 (61–79) | 10mg/m2/12h×14d | 10-14mg/m2/d×4d | 54.55 |
| Li[47] | 18 | AML (R/R) | 38 (19–65) | 10mg/m2/12h×14d | 5-7mg/m2/d×8d | 72.22 |
| Chen[39] | 34 | AML (ND & Elderly) | 69.5 (60–85) | 10mg/m2/12h×14d | 14mg/m2/d×8d | 67.65 |
| Wei[36] | 20 | AML (R/R) | 38 (12–66) | 10mg/m2/12h×14-28d | 20mg/d×4d | 75 |
| Yi[48] | 24 | AML | NR (54–79) | 10mg/m2/12h×14d | 10mg/m2/d×7d | 25 |
| Su[74] | 33 | MDS/t-AML | 60 (28–77) | 25mg/d×14d | 10mg/d×8d | 42.42 |
| Long[70] | 20 | AML (Elderly) | 70 (60–81) | 25mg/m2/12h×14d | 9mg/m2/d×7d | 65 |
| Zhan[50] | 21 | AML (Elderly) | 68 (60–77) | 10mg/m2/12h×14d | 14mg/m2/d×4d | 66.67 |
Abbreviations: CR = Complete response; ND = newly diagnosed; R/R = relapsed/refractory; NR = not reported.